Pharmaceutical Technology and D&B Launch Business Marketplace - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology and D&B Launch Business Marketplace


Pharmaceutical Technology has joined with Dun & Bradstreet Credibility Corp. to launch the Pharmaceutical Technology and BioPharm International Marketplace, an online community developed to bring pharmaceutical buyers and suppliers together with Industry leading thought-leadership content from the publications, in-depth product information from suppliers, and real time social media features that allow members to integrate their company social media feeds into their profiles. Buyers will have the ability to rate and comment on products and services from suppliers.

Advanstar, publisher of pharmaceutical life science publications including Pharmaceutical Technology, is the first B2B publisher to embrace the online Credibility Review Business Marketplace platform developed by Dun & Bradstreet Credibility Corp.

“We are very excited about this opportunity. Given the high costs of developing eDirectories and continually upgrading and supporting these platforms across a wide array of publications, an alternative that leveraged lower upfront costs and scalability with speed to market was very attractive,” said Advanstar Executive Vice-President, Ron Wall.

According to eMarketer’s latest report, digital spending in pharmaceutical and healthcare marketing is forecasted to grow 57% to $2.48 billion by 2016. “Our vision is to create the largest and most dynamic communities of buyers and suppliers with Dun & Bradstreet Credibility Corp., so we can take full advantage of this spending growth,” said Wall.

According to Jeff Stibel, Chairman and CEO, Dun & Bradstreet Credibility Corp., “what we offer is a highly respected and branded platform with enhanced credibility data and information from our database, world class development expertise that will allow all of the Marketplace sites to benefit from ongoing upgrades and enhancements and a seamless integration of social media.”

The new Pharmaceutical Technology/BioPharm International Marketplace will concentrate on business information and news on companies in analytical/lab equipment, contract services, manufacturing equipment, packaging equipment/supplies, pharm/biopharm ingredients, and process control/IT.

Advanstar Life Sciences group will launch additional eDirectories supported by their other publications on the Dun & Bradstreet Credibility Review Marketplace in the coming months. Advanstar Communications Inc. is a leading marketing, media and events company providing integrated solutions for Fashion, Licensing, Life Sciences and Powersports industries. Advanstar serves business professionals and consumers in these industries with its portfolio of 141 events, 60 publications and directories, 233 electronic products, as well as educational and direct marketing products to facilitate commerce by connecting buyers and sellers across its vertical markets.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here